Lineage Cell Therapeutics (LCTX) Asset Writedowns and Impairment (2010 - 2025)
Lineage Cell Therapeutics (LCTX) reported Asset Writedowns and Impairment of $14.8 million for Q2 2025, up 9900.0% quarter-over-quarter from $148000.0 in Q4 2016.
Lineage Cell Therapeutics (LCTX) Asset Writedowns and Impairment (2010 - 2025) Analysis & Trends
Lineage Cell Therapeutics has reported Asset Writedowns and Impairment for 7 years, with the latest figure at $14.8 million in Q2 2025.
- For the quarter ending Q2 2025, Asset Writedowns and Impairment changed N/A year-over-year to $14.8 million; the trailing twelve-month figure through Dec 2025 stood at $14.8 million (up 9900.0% YoY), and the FY2025 full-year result was $14.8 million, changed N/A from the prior year.
- Asset Writedowns and Impairment for Q2 2025 stood at $14.8 million, up from $148000.0 in the prior quarter.
- The five-year high for Asset Writedowns and Impairment was $14.8 million in Q2 2025, with the low at $14.8 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Lineage Cell Therapeutics | 303.84 Mn | 239.94 Mn | 1.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 14.80 Mn |
| Jun 30, 2025 | 14.80 Mn |
| Dec 31, 2016 | 148,000.00 |
| Dec 31, 2016 | 148,000.00 |
| Sep 30, 2016 | 448,000.00 |
| Sep 30, 2016 | 448,000.00 |
| Dec 31, 2014 | -25,000.00 |
| Dec 31, 2014 | -25,000.00 |
| Sep 30, 2014 | -12,000.00 |
| Sep 30, 2014 | -12,000.00 |
| Jun 30, 2014 | 12,424.00 |
| Jun 30, 2014 | 12,424.00 |
| Mar 31, 2014 | 8,576.00 |
| Mar 31, 2014 | 8,576.00 |
| Dec 31, 2013 | 120.00 |
| Dec 31, 2013 | 120.00 |
| Sep 30, 2013 | -5,830.00 |
| Sep 30, 2013 | -5,830.00 |
| Jun 30, 2013 | -813.00 |
| Jun 30, 2013 | -813.00 |